Team members for the Curevc
William (Bill) Amsbaugh is a Partner and Chief Technology Officer (CTO) at Cure Ventures where he heads the firm’s bioinformatics efforts. His career spans 25 years across a variety of technical domains combining his training as an analytical chemist with his expertise in computer science. Bill has been focused on accelerating drug discovery and commercialization […]
William Amsbaugh, M.S. Read More »
Dr. Cicmil (Milenko) has over 20 years of experience in drug discovery and development, leading multi-disciplinary scientific/project teams, portfolio strategy, and business development. His deep understanding of biology, especially in inflammation/autoimmunity and oncology matched with his drug development experience across small molecules, biologics and peptides enables him to find creative solutions for challenges faced by
Milenko Cicmil, Ph.D. Read More »
Mr. Fallace (Dave) is a Managing Partner and Co-Founder of Cure Ventures. He has made investments in venture capital and alternative asset funds for over 20 years. He served as a member of the investment committee of several large multibillion-dollar firms overseeing alternative investment portfolios. Across these portfolios he made investments as a limited partner
David Fallace, J.D. / M.B.A. Read More »
Jeno is a seasoned biotech professional with over three decades of experience in the industry. Throughout his career, his primary focus has been translating promising scientific discoveries into impactful therapies and fostering the growth of early-stage start-up companies. Jeno has gained extensive scientific leadership and company-building experience, having assembled, led, and mentored high-performing R&D organizations.
Jeno Gyuris, Ph.D. Read More »
Dr. Han (May) has over 20 years of experience in drug discovery and development. May’s experience includes being both a drug program manager and a scientific team lead, encompassing more than 20 programs across a variety of drug modalities, including small molecule, complex biologics, cell therapies. She worked at Millennium Pharmaceuticals, AVEO and Novartis in
Dr. Jonas (Jeff) is a Partner at Cure Ventures and brings over two decades of experience in R&D leadership and cutting-edge CNS drug discovery and development across medicines and brands that have successfully helped millions of patients, such as Lexapro, Vyvanse, Zulresso, Zurzuvae and Namenda. Dr. Jonas’ significant company-building and advisory experience has generated considerable
Jeffrey M. Jonas, MD Read More »
Kayarash is a Senior Associate at Cure Ventures, where he focuses on company creation efforts. His work at Cure is driven by a mission to develop transformative medicines through a culture rooted in scientific rigor, creativity, and patient-centric innovation. Kayarash earned his PhD at the Johns Hopkins University School of Medicine as a National Science
Kayarash Karimian, Ph.D. Read More »
Mr. King (Drew) is a Partner and the Chief Financial Officer of Cure Ventures. He oversees the financial and operational functions at the Firm and our early-stage portfolio companies. Drew has over 15 years of experience in finance and operations supporting both private and capital market funds. He most recently was the Vice President of
Drew King, CPA / M.S.A. Read More »
Dr. King (Virginia Lyle) is a Senior Associate of Cure Ventures with over 10 years of research experience. As a member of the Cure Ventures team, Lyle is involved in sourcing new deals, conducting due diligence, and assisting with company creation endeavors. Most recently, she worked at the University of Connecticut as a graduate researcher
Virginia Lyle King, Ph.D. Read More »
Rich’s career in the life science sector spans three decades demonstrating strategic and corporate development leadership within the biotech industry as well as investment leadership at top-performing venture capital firms. He is considered a trusted partner to visionary scientists and entrepreneurs, by being directly involved in the early capital raises of leading prominent biotech start-ups.
Richard J. Lim, M.B.A. Read More »
